Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Baijun Fang

Showing results (71-80 of 83) with videos related to

Pageof 9
Sort By:
BMC Cancer|May 7, 2025
Real-world analysis of treatment patterns, effectiveness, and safety of daratumumab-based regimens in Chinese patients with newly diagnosed or relapsed/refractory multiple myelomaLuqun Wang, Wei Yang, Yafei Wang, et al.
Annals of Hematology|April 12, 2026
Treatment patterns, effectiveness, and safety of daratumumab-based regimens in Chinese patients with multiple myeloma: longer follow-up of the real-world MMY4032 studyWei Yang, Luqun Wang, Yafei Wang, et al.
Journal of Medical Genetics|July 15, 2017
Assessing genome-wide copy number variation in the Han Chinese populationJianqi Lu, Haiyi Lou, Ruiqing Fu, et al.
International Journal of Cancer|February 20, 2021
miR-17-3p promotes the proliferation of multiple myeloma cells by downregulating P21 expression through LMLN inhibitionPu Xiang, Yiu To Yeung, Jiheng Wang, et al.
International Journal of Hematology|January 3, 2021
A study of carfilzomib and dexamethasone in patients with relapsed and refractory multiple myeloma in ChinaJuan Du, Baijun Fang, Jian Li, et al.
Chinese Medical Journal|May 29, 2025
Real-world outcomes of isatuximab with pomalidomide and dexamethasone for relapsed and/or refractory multiple myelomaWenting Chen, Jianhua You, Li'e Lin, et al.
British Journal of Haematology|July 7, 2024
Multiple small-dose infusions of G-CSF-mobilized haploidentical lymphocytes after autologous haematopoietic stem cell transplantation for acute myeloid leukaemiaFei Yang, Quan Ren, Yingling Zu, et al.
BMC Medicine|April 5, 2022
Selinexor plus low-dose dexamethasone in Chinese patients with relapsed/refractory multiple myeloma previously treated with an immunomodulatory agent and a proteasome inhibitor (MARCH): a phase II, single-arm studyLugui Qiu, Zhongjun Xia, Chengcheng Fu, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|March 28, 2025
CLO25-072: A Multicenter, Randomized, Controlled, Non-Inferiority Study of Narlumosbart Compared With Denosumab in the Treatment of Bone Disease in Patients With Multiple MyelomaHonghui Huang, Fei Li, Yan Xu, et al.
Thrombosis Journal|October 4, 2023
Development and validation of a new risk assessment model for immunomodulatory drug-associated venous thrombosis among Chinese patients with multiple myelomaXiaozhe Li, Xiuli Sun, Baijun Fang, et al.
Pageof 9

Showing results (71-80 of 83) with videos related to

Sort By:
Pageof 9
BMC Cancer|May 7, 2025
Real-world analysis of treatment patterns, effectiveness, and safety of daratumumab-based regimens in Chinese patients with newly diagnosed or relapsed/refractory multiple myelomaLuqun Wang, Wei Yang, Yafei Wang, et al.
Annals of Hematology|April 12, 2026
Treatment patterns, effectiveness, and safety of daratumumab-based regimens in Chinese patients with multiple myeloma: longer follow-up of the real-world MMY4032 studyWei Yang, Luqun Wang, Yafei Wang, et al.
Journal of Medical Genetics|July 15, 2017
Assessing genome-wide copy number variation in the Han Chinese populationJianqi Lu, Haiyi Lou, Ruiqing Fu, et al.
International Journal of Cancer|February 20, 2021
miR-17-3p promotes the proliferation of multiple myeloma cells by downregulating P21 expression through LMLN inhibitionPu Xiang, Yiu To Yeung, Jiheng Wang, et al.
International Journal of Hematology|January 3, 2021
A study of carfilzomib and dexamethasone in patients with relapsed and refractory multiple myeloma in ChinaJuan Du, Baijun Fang, Jian Li, et al.
Chinese Medical Journal|May 29, 2025
Real-world outcomes of isatuximab with pomalidomide and dexamethasone for relapsed and/or refractory multiple myelomaWenting Chen, Jianhua You, Li'e Lin, et al.
British Journal of Haematology|July 7, 2024
Multiple small-dose infusions of G-CSF-mobilized haploidentical lymphocytes after autologous haematopoietic stem cell transplantation for acute myeloid leukaemiaFei Yang, Quan Ren, Yingling Zu, et al.
BMC Medicine|April 5, 2022
Selinexor plus low-dose dexamethasone in Chinese patients with relapsed/refractory multiple myeloma previously treated with an immunomodulatory agent and a proteasome inhibitor (MARCH): a phase II, single-arm studyLugui Qiu, Zhongjun Xia, Chengcheng Fu, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|March 28, 2025
CLO25-072: A Multicenter, Randomized, Controlled, Non-Inferiority Study of Narlumosbart Compared With Denosumab in the Treatment of Bone Disease in Patients With Multiple MyelomaHonghui Huang, Fei Li, Yan Xu, et al.
Thrombosis Journal|October 4, 2023
Development and validation of a new risk assessment model for immunomodulatory drug-associated venous thrombosis among Chinese patients with multiple myelomaXiaozhe Li, Xiuli Sun, Baijun Fang, et al.
Pageof 9